Virtual Event

2025年5月06日 (火) 午後 3:00 - 2025年5月08日 (木) 午後 7:30

(Central Europe Standard Time)

4051 Basel, Switzerland

Artificial Intelligence in Pharmacovigilance

JUST A FEW SEATS LEFT! A practical orientation virtual live training course for the next level of pharmacovigilance technology as it is being implemented across the industry.

学部

Andrew  Mitchell

Andrew Mitchell

CEO and Founder, YEZA.ai, United States

Andrew is the CEO/Founder of YEZA.ai, delivering AI-Agents for Safety Intake that's transforming Pharmacovigilance. He has consistently led at the forefront of innovation, having successfully delivered two next-gen Safety systems and holds 3 US-patents related to Clinical and PV technology. A 'no nonsense' reputation built on 25 years of experience in software design, development, strategy, implementation, marketing, and go-to-market activities. Extensive experience with Oracle Argus, ArisGlobal LSMV, Veeva Vault Safety and Medidata Rave.

Jan  Petracek, MD, MSc

Jan Petracek, MD, MSc

CEO, Ivigee, Czech Republic

Jan is a passionate and visionary leader in the field of pharmacovigilance, with over 20 years of experience in the industry. He is the CEO of iVigee, a company that provides innovative and sustainable solutions for drug safety and risk management. He is also a Fellow of the International Society of Pharmacovigilance (FISoP), a Global Fellow in Medicines Development (GFMD), and a Qualified Person for Pharmacovigilance (QPPV). Jan has a proven track record of establishing, growing, and selling successful organizations, both for-profit and non-profit, in the pharmacovigilance sector. He has received multiple awards and recognitions, including the DIA Excellence in Service Award in 2018 and HM Queen's Award for International Trade in 2019.

Phil  Tregunno

Phil Tregunno

Deputy Director - Patient Safety Monitoring, Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

Phil is the Deputy Director of Patient Safety Monitoring within MHRA’s Safety & Surveillance function and has over twenty years of experience working in pharmacovigilance. Prior to his current role Phil spent fourteen years leading and developing the pharmacovigilance system, including technology, processes, and relevant aspects of Pharmacovigilance Legislation. He is now accountable for Patient Safety Monitoring across medicines, vaccines, devices, defects and blood products. Phil was responsible delivery of MHRA systems for COVID-19 vaccine surveillance and their integration into the healthcare system. For several years he has led international projects to develop and deliver tools for global pharmacovigilance.

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。